• About
  • Submit Article/PR
  • Contact
Sunday, June 1, 2025
No Result
View All Result
  • Login
The Healthcare Daily
WHO COVID DASHBOARD
  • Home
  • News
    • All
    • Biotech
    • By Speciality
    • Generic Drugs
    • Insurance
    • Investment
    • Medical Tourism
    • Pharma
    Ixchiq-the-Chikungunya-Vaccine-Receives-FDA-Approval-thehealthcaredaily

    Ixchiq, the Chikungunya Vaccine, Receives FDA Approval!

    WHO-Emergency-Meeting-Scheduled-Amidst-Gaza-and-West-Bank-Health-Crisis-thehealthcaredaily

    WHO Emergency Meeting Scheduled Amidst Gaza and West Bank Health Crisis

    Controversy-Surrounds-NMC's-Logo-Featuring-Hindu-Deity-thehealthcaredaily

    Controversy Surrounds NMC’s Logo Featuring Hindu Deity

    Bollywood-Star-Ranveer-Singh-Bold-Step-Into-Sexual-Health-Advocacy-thehealthcaredaily

    Bollywood Star Ranveer Singh’s Bold Step Into Sexual Health Advocacy

    Said-Pneumonia-Outbreak-in-China-Prompts-Concerns-Among-Indian-States-thehealthcaredaily

    Said Pneumonia Outbreak in China Prompts Concerns in Indian States

    World-AIDS-Day-2023-Communities-Commended-for-Pioneering-Efforts-in-HIV-Response-thehealthcaredaily

    World AIDS Day 2023: Communities Commended for Pioneering Efforts in HIV Response

    Health-Community-Raises-Urgent-Climate-Change-and-Health-Concerns-Ahead-of-COP28-thehealthcaredaily

    Health Community Raises Urgent Climate Change and Health Concerns Ahead of COP28

    Indian-Health-Ministry-Urge- Vigilance-as-Respiratory-Illness-Clusters-Emerge-thehealthcaredaily

    Indian Health Ministry Urges Vigilance as Respiratory Illness Clusters Emerge in China

    Health-Crisis-in-Gaza-Continue-sWHO's-High-Risk-Evacuation-Mission-thehealthcaredaily

    Health Crisis in Gaza Continues, WHO’s High-Risk Evacuation Mission

  • Insights
    • All
    • Analysis
    • Interview
    • Opinion
    • Reports
    Gynecomastia

    Gynecomastia: Balancing Act – Dangers, Benefits, and Decision-Making

    Inspiring Journeys to Health and Wellness

    Medical Tourism Success Stories: Inspiring Journeys to Health and Wellness

    Wellness Tourism: Understanding Its Mind-Boggling Significance in Your Life

    World-AIDS-Day-2023-Communities-Commended-for-Pioneering-Efforts-in-HIV-Response-thehealthcaredaily

    World AIDS Day 2023: Communities Commended for Pioneering Efforts in HIV Response

    Understanding-Allergies-Identifying-Triggers-and-Seeking-Effective-Treatments-thehealthcaredaily

    Allergies Insight: Identifying Triggers and Pursuing Effective Remedial Measures

    Exploring-Women's-Reproductive-Right-A-Fundamental-Introduction-thehealthcaredaily

    Exploring Women’s Reproductive Rights: A Fundamental Introduction

    Managing Autoimmune Disorders: Lifestyle and Diet Strategies

    Understanding Celiac Disease: Symptoms, Causes, and Diagnosis

    Understanding-Multiple-Sclerosis-Symptoms-Causes,-and-Treatments-thehealthcaredaily

    Understanding Multiple Sclerosis: Symptoms, Causes, and Treatments

  • HealthTech
    • All
    • Hardware
    • Innovation
    • Software
    Augmenting Humanity

    Navigating the Ethical Frontiers of Technological Enhancement – Augmenting Humanity

    Leading Healthcare Cybersecurity Firms: The Best 5

    AI-Powered Diagnostics: Revolutionizing Healthcare with Speed and Precision

    Aidoc Secures $30 Million Funding to Revolutionize AI Imaging

    Telemedicine-in-Healthcare-2023-An-Evaluation-of-Its-Advantages-and-Disadvantages-thehealthcaredaily

    Telemedicine in Healthcare: An Evaluation of Its Advantages and Disadvantages

    A Journey into the Brain: Exploring the Wonders of Deep Brain Stimulation

    Everything-about-Personalized-Medicine-in-2023-Healthcare-Daily

    The Promise of Personalized Medicine: Unlocking a Better Future of Medicine

    10-Most-Promising-Breakthroughs-in-Medical-Research-Thehealthcaredaily

    10 Most Promising Breakthroughs in Medical Research

    Overview-of-healthcare-hackathons-and-competitions-focused-on-healthcare-innovation-thehealthcaredaily

    Overview of healthcare hackathons and competitions focused on healthcare innovation

  • Pharma
  • Events
  • NewsMakers
  • World
  • Home
  • News
    • All
    • Biotech
    • By Speciality
    • Generic Drugs
    • Insurance
    • Investment
    • Medical Tourism
    • Pharma
    Ixchiq-the-Chikungunya-Vaccine-Receives-FDA-Approval-thehealthcaredaily

    Ixchiq, the Chikungunya Vaccine, Receives FDA Approval!

    WHO-Emergency-Meeting-Scheduled-Amidst-Gaza-and-West-Bank-Health-Crisis-thehealthcaredaily

    WHO Emergency Meeting Scheduled Amidst Gaza and West Bank Health Crisis

    Controversy-Surrounds-NMC's-Logo-Featuring-Hindu-Deity-thehealthcaredaily

    Controversy Surrounds NMC’s Logo Featuring Hindu Deity

    Bollywood-Star-Ranveer-Singh-Bold-Step-Into-Sexual-Health-Advocacy-thehealthcaredaily

    Bollywood Star Ranveer Singh’s Bold Step Into Sexual Health Advocacy

    Said-Pneumonia-Outbreak-in-China-Prompts-Concerns-Among-Indian-States-thehealthcaredaily

    Said Pneumonia Outbreak in China Prompts Concerns in Indian States

    World-AIDS-Day-2023-Communities-Commended-for-Pioneering-Efforts-in-HIV-Response-thehealthcaredaily

    World AIDS Day 2023: Communities Commended for Pioneering Efforts in HIV Response

    Health-Community-Raises-Urgent-Climate-Change-and-Health-Concerns-Ahead-of-COP28-thehealthcaredaily

    Health Community Raises Urgent Climate Change and Health Concerns Ahead of COP28

    Indian-Health-Ministry-Urge- Vigilance-as-Respiratory-Illness-Clusters-Emerge-thehealthcaredaily

    Indian Health Ministry Urges Vigilance as Respiratory Illness Clusters Emerge in China

    Health-Crisis-in-Gaza-Continue-sWHO's-High-Risk-Evacuation-Mission-thehealthcaredaily

    Health Crisis in Gaza Continues, WHO’s High-Risk Evacuation Mission

  • Insights
    • All
    • Analysis
    • Interview
    • Opinion
    • Reports
    Gynecomastia

    Gynecomastia: Balancing Act – Dangers, Benefits, and Decision-Making

    Inspiring Journeys to Health and Wellness

    Medical Tourism Success Stories: Inspiring Journeys to Health and Wellness

    Wellness Tourism: Understanding Its Mind-Boggling Significance in Your Life

    World-AIDS-Day-2023-Communities-Commended-for-Pioneering-Efforts-in-HIV-Response-thehealthcaredaily

    World AIDS Day 2023: Communities Commended for Pioneering Efforts in HIV Response

    Understanding-Allergies-Identifying-Triggers-and-Seeking-Effective-Treatments-thehealthcaredaily

    Allergies Insight: Identifying Triggers and Pursuing Effective Remedial Measures

    Exploring-Women's-Reproductive-Right-A-Fundamental-Introduction-thehealthcaredaily

    Exploring Women’s Reproductive Rights: A Fundamental Introduction

    Managing Autoimmune Disorders: Lifestyle and Diet Strategies

    Understanding Celiac Disease: Symptoms, Causes, and Diagnosis

    Understanding-Multiple-Sclerosis-Symptoms-Causes,-and-Treatments-thehealthcaredaily

    Understanding Multiple Sclerosis: Symptoms, Causes, and Treatments

  • HealthTech
    • All
    • Hardware
    • Innovation
    • Software
    Augmenting Humanity

    Navigating the Ethical Frontiers of Technological Enhancement – Augmenting Humanity

    Leading Healthcare Cybersecurity Firms: The Best 5

    AI-Powered Diagnostics: Revolutionizing Healthcare with Speed and Precision

    Aidoc Secures $30 Million Funding to Revolutionize AI Imaging

    Telemedicine-in-Healthcare-2023-An-Evaluation-of-Its-Advantages-and-Disadvantages-thehealthcaredaily

    Telemedicine in Healthcare: An Evaluation of Its Advantages and Disadvantages

    A Journey into the Brain: Exploring the Wonders of Deep Brain Stimulation

    Everything-about-Personalized-Medicine-in-2023-Healthcare-Daily

    The Promise of Personalized Medicine: Unlocking a Better Future of Medicine

    10-Most-Promising-Breakthroughs-in-Medical-Research-Thehealthcaredaily

    10 Most Promising Breakthroughs in Medical Research

    Overview-of-healthcare-hackathons-and-competitions-focused-on-healthcare-innovation-thehealthcaredaily

    Overview of healthcare hackathons and competitions focused on healthcare innovation

  • Pharma
  • Events
  • NewsMakers
  • World
No Result
View All Result
The Healthcare Daily
No Result
View All Result
Home Press Release

MicroOptx Completes Patient Enrollment in Initial Phase of U.S. Pivotal Clinical Trial for the Beacon Aqueous Microshunt

by Admin
August 3, 2020
in Press Release
Reading Time: 3 mins read
0
0
SHARES
Share on FacebookShare on Twitter

MINNEAPOLIS, July 30, 2020 /PRNewswire/ — MicroOptx Inc., a medical device innovator with a platform technology to change the way the world treats glaucoma, today announced the completion of enrollment in the initial phase of the Beacon Study. This is the U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical trial of the Beacon Aqueous Microshunt. Study participants treated during the initial phase of the interventional, single-arm, open label, multicenter clinical trial will be followed to evaluate safety, performance, and intraocular pressure (IOP) reduction. These results will form the basis of trial expansion to include a total of 90 implanted eyes. The primary effectiveness outcome will be intraocular pressure (IOP) reduction. 

The Beacon device distinguishes itself from other implantable glaucoma devices in that it lowers and controls IOP by shunting aqueous humor (AH) directly to the tear film rather than an enclosed space inside the eye. This approach allows more precise and consistent IOP control that may help regulate the progression of glaucoma. The implant procedure involves a 1.4mm incision followed by simple insertion of the device into the anterior chamber. It is designed for use in patients with their natural lens and those in which the natural lens has been removed and replaced with an artificial lens. The U.S. pivotal clinical trial is only for refractory glaucoma patients undergoing a standalone procedure, though multiple concomitant (with cataract surgery) procedures have been performed in an otherwise similar European study. 

In addition to the U.S. pivotal clinical trial to evaluate the Beacon device, MicroOptx is also conducting the Early BiRD (EU) trial at investigational centers in Europe. It is ongoing with about 25 percent of study participants beyond their 1-year follow-up. Results of the initial cohort have been published in the most recent issue of the Journal of Cataract and Refractive Surgery. MicroOptx has also completed enrollment in its U.S. feasibility study that is being conducted under an IDE as part of the FDA’s Early Feasibility Studies program. The longest follow-up duration available from this study is two years. 

“The Beacon device represents the next generation in Micro-Invasive Glaucoma Surgery devices, or MIGS, striving for trabeculectomy effectiveness without the complications and required maintenance,” said Chris Pulling, MicroOptx Chief Executive Officer. “Completion of enrollment in the initial phase of the Beacon clinical trial marks achievement of an important milestone in bringing this transformative therapy to patients and providers. To achieve this milestone, in just over one month and in the current COVID environment, is a testament to the great team at MicroOptx and the enthusiasm of our clinician partners and the patients they care for.”

Glaucoma is characterized by progressive, irreversible and largely asymptomatic vision loss caused by optic nerve damage. There is no cure for this disease, and reducing intraocular pressure is the only proven treatment. According to Market Scope, approximately 80 million people worldwide have glaucoma, including 4.5 million people in the United States. The vast majority of glaucoma sufferers worldwide currently have no access to any effective therapy and are needlessly blind or going blind.

The Beacon device is an investigational, first-generation device. MicroOptx is currently pursuing its initial regulatory approvals to commercialize the device in the United States, Canada, and the European Union.

About MicroOptx
MicroOptx (www.microoptx.com) is an ophthalmic medical technology company focused on the development and commercialization of platform technology that shunts aqueous humor to the surface of the eye. Its current focus is to use this technology to create a safe, simple, transformative treatment for glaucoma – the world’s leading cause of irreversible blindness – by normalizing intraocular pressure at a range low enough to halt the progression to blindness for most glaucoma patients. The company expects European market approval in 2021 and U.S. and Canada market approval in 2022.

SOURCE MicroOptx

Related Links

https://microoptx.com/

Admin

Admin

Next Post

Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes

Recommended

Serum-Institute-of-India-Vaccine-rat-race

Will Public Health be compromised to win the race of vaccine discovery?

5 years ago
Unzipping Some Popular Myths About Menstruation!

Unzipping Some Popular Myths About Menstruation!

4 years ago

About Us

A daily dose of news, views, opinions, and actionable information from the global healthcare industry. Our newsletter is available for a limited audience. If you are interested to write or contribute to this portal then please get in touch.

Important Links

  • Home
  • World
  • Business
  • Health

Recent News

Gynecomastia: Balancing Act – Dangers, Benefits, and Decision-Making

Medical Tourism Success Stories: Inspiring Journeys to Health and Wellness

  • About
  • Submit Article/PR
  • Contact

© 2025 - The Healthcare Daily

No Result
View All Result
  • Home
  • World
  • Business
  • Health

© 2025 - The Healthcare Daily

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In